FDA Drug Abuse Advisory Committee
Executive Summary
Status of Astra's Dalgan Injection (dezocine) postmarketing surveillance of abuse and diversion will be addressed at the Feb. 4 meeting. Panel also will discuss the abuse liability of Bristol- Myers Squibb's Stadol Nasal Spray (butorphanol tartrate). On Feb. 5, the committee will address guideline development for assessing abuse liability of drugs and the status of guideline development for medications to treat drug dependence and abuse. Committee will meet at 9 a.m. both days at FDA's Parklawn building in conference rooms D & E.